Funding Received
$67.5 Million in 2 Rounds from 5 Investors
Most Recent Funding
$57 Million Series B on April 10, 2014
Headquarters:
Edinburgh
Description:
NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Categories:
Biotechnology
Website:
http://www.nucanabiomed.com

Detailed Description

Update

NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.

Current Team (3)

Update

Funding Rounds (2) - $67.5M

Update

Board Members and Advisors (3)

Update

Investors (5)

Update

Offices/Locations (1)

Update
  • Office

    10 Lochside Place

    Edinburgh, EH12 9RG

    GBR

Images (1)

Update
  • At0m3jfbqzz39iif2p87